GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Speaker4Good day, and thank you for standing by. Welcome to the GeneDx third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one-one on your telephone. You will then hear an automated message advising your hand is raised. To start a question, please ...

Core Insights - GeneDx is positioned as a leader in genomics and rare-disease diagnostics, with significant growth potential highlighted by recent FDA designations and strong sales performance [2][3][4]. Company Overview - GeneDx, based in Stamford, Connecticut, specializes in rare-disease diagnosis and has developed GeneDx Infinity, the largest rare-disease dataset from 25 years of genomic tests [2]. - The company aims to transition healthcare from reactive to proactive approaches [2]. Financial Performance - Over the last six quarters, GeneDx has reported sales growth between 40% and 67%, with a 46% increase in revenue to $102.7 million in the third quarter [3]. - Earnings per share surged by 725% to 50 cents, compared to a loss in the previous year [3]. - Analysts project a 37% sales growth to $104.7 million and a 954% increase in earnings to 42 cents per share for the upcoming report [4]. Market Demand and Stock Performance - The strong growth trajectory has led to increased demand for GeneDx stock, reflected in a B+ Accumulation/Distribution Rating and a 1.2 up/down volume ratio [5]. - The number of funds holding GeneDx shares rose from 359 to 390, indicating growing institutional interest [5]. - GeneDx holds a 98 Composite Rating, outperforming 98% of stocks based on key fundamental and technical factors [5]. Technical Analysis - GeneDx stock is currently in a first-stage consolidation pattern, with a buy point set at 136 [6]. - A short-term concern is the 21-day exponential moving average falling below the 50-day moving average, which investors should monitor for signs of technical recovery [6].